Cardiac Resynchronization Therapy (CRT)

Guideline-Directed Medical and Device Therapy in Heart Failure: Insights from theESC Heart Failure III Registry in Armenia

by Prateek Chopra | May 24, 2026 | Cardiology Conferences | ESC-HF 2026 Guideline-directed medical therapy (GDMT) and device-based interventions are well established to improve outcomes in patients with heart failure (HF). However, implementation of evidence-based therapies varies considerably across healthcare systems and may be influenced by drug availability, healthcare infrastructure, and reimbursement policies. Using data from the European Society of […]

Effect of Sacubitril/Valsartan and SGLT2 Inhibitors on Echocardiographic Responseand Clinical Outcomes A er Cardiac Resynchroniza on Therapy: Insights froma Real-world Cohort

by Prateek Chopra | May 23, 2026 | Cardiology Conferences | ESC-HF 2026 Cardiac resynchronization therapy (CRT) is recommended for symptomatic heart failure (HF) patients with prolonged QRS duration and reduced left ventricular ejection fraction (LVEF), although pivotal CRT trials predated widespread use of angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose co-transporter-2 inhibitors (SGLT2i). This study evaluated whether contemporary HF therapy influences

Effect of Sacubitril/Valsartan and SGLT2 Inhibitors on Echocardiographic Responseand Clinical Outcomes A er Cardiac Resynchroniza on Therapy: Insights froma Real-world Cohort Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Cardiac Resynchronization Therapy (CRT), Guideline-Directed Medical Therapy (GDMT), Heart Failure with Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan (ARNI), SGLT2 Inhibitors